NOACs to recover from slow initial uptake

Even in cost-conscious markets such as the UK, physicians envision a dramatic shift towards NOACs


(Photo Courtesy:

The use of novel oral anticoagulants (NOACs) will see a substantial rise in the anticoagulation market space after an initially sluggish uptake, and will start to be elected over warfarin, the current standard-of-care product in certain indications, according to an analyst with research and consulting firm GlobalData.

Dr Lakshmi Dharmarajan, GlobalData's Senior Analyst covering Cardiovascular and Metabolic Disorders, states that: "NOACs are increasingly being used in patients with venous thromboembolism (VTE) due to the drugs' rapid onset of action and the ability to be administered in fixed doses without the need for regular coagulation monitoring.

"Among the VTE population, the fastest to adopt NOACs have been the orthopedic patient segments, for the prevention of deep vein thrombosis (DVT)."

For those with DVT, Xarelto has been demonstrated by real-world studies to have economic advantages over standard-of-care treatments.

As Dr Dharmarajan explains: "Positive evidence such as shorter hospital stays, in addition to the obvious clinical benefits of these drugs, will encourage payers and healthcare systems to recognize their financial advantages over existing treatments.


Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email